| pubmed-article:16214655 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16214655 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16214655 | lifeskim:mentions | umls-concept:C0002895 | lld:lifeskim |
| pubmed-article:16214655 | lifeskim:mentions | umls-concept:C0015392 | lld:lifeskim |
| pubmed-article:16214655 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16214655 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:16214655 | lifeskim:mentions | umls-concept:C2348519 | lld:lifeskim |
| pubmed-article:16214655 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:16214655 | pubmed:dateCreated | 2005-10-10 | lld:pubmed |
| pubmed-article:16214655 | pubmed:abstractText | Ocular complications of the sickling disorders are multiple and require continuing assessment to detect lesions early enough for effective prophylactic therapy to maximize visual functioning. The disease requires close monitoring of the patient for progression or regression of lesions in determining the selection of therapeutic options. | lld:pubmed |
| pubmed-article:16214655 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16214655 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16214655 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16214655 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16214655 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16214655 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16214655 | pubmed:issn | 0889-8588 | lld:pubmed |
| pubmed-article:16214655 | pubmed:author | pubmed-author:LuttyGerard... | lld:pubmed |
| pubmed-article:16214655 | pubmed:author | pubmed-author:EmersonGeoffr... | lld:pubmed |
| pubmed-article:16214655 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16214655 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:16214655 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16214655 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16214655 | pubmed:pagination | 957-73, ix | lld:pubmed |
| pubmed-article:16214655 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16214655 | pubmed:meshHeading | pubmed-meshheading:16214655... | lld:pubmed |
| pubmed-article:16214655 | pubmed:meshHeading | pubmed-meshheading:16214655... | lld:pubmed |
| pubmed-article:16214655 | pubmed:meshHeading | pubmed-meshheading:16214655... | lld:pubmed |
| pubmed-article:16214655 | pubmed:meshHeading | pubmed-meshheading:16214655... | lld:pubmed |
| pubmed-article:16214655 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16214655 | pubmed:articleTitle | Effects of sickle cell disease on the eye: clinical features and treatment. | lld:pubmed |
| pubmed-article:16214655 | pubmed:affiliation | Casey Eye Institute, Portland, OR 97239, USA. | lld:pubmed |
| pubmed-article:16214655 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16214655 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16214655 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:16214655 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16214655 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16214655 | lld:pubmed |
